Wellinks has secured $10 million in Series B funding, marking another milestone in the company’s mission to improve care for people living with chronic respiratory diseases. The latest investment will help the healthcare technology company strengthen its virtual care platform, expand its clinical programs, and support more patients and healthcare providers with remote respiratory care solutions.
Funding to Accelerate Growth
The Series B financing provides Wellinks with fresh capital to continue expanding its virtual respiratory care services. The company plans to use the investment to enhance its technology platform, grow its clinical operations, and increase the availability of its care programs for patients with chronic respiratory conditions.
The funding comes as healthcare organizations continue to adopt digital care models that enable patients to receive ongoing support from home while staying connected with their healthcare teams.
Improving Care for Patients with Chronic Respiratory Disease
Headquartered in New Haven, Connecticut, Wellinks delivers virtual cardiopulmonary care designed for people living with chronic respiratory diseases, including chronic obstructive pulmonary disease (COPD). The company’s platform combines remote patient monitoring, connected devices, personalized care plans, and one-on-one clinical coaching to help patients better manage their health between in-person medical visits.
Wellinks also provides patients with access to healthcare professionals through phone, video, and text-based support. This continuous engagement is intended to help patients stay on track with their treatment plans while giving care teams greater visibility into a patient’s condition.
Technology Focused on Continuous Care
The company’s virtual care platform is built around continuous monitoring and predictive patient insights. By combining wearable technology with remote monitoring and clinical support, Wellinks helps healthcare providers identify potential health concerns earlier and respond before symptoms become more serious.
According to the company, its programs are designed to support healthcare providers and payers by improving patient outcomes while lowering the overall cost of care through proactive disease management.
Expanding Virtual Respiratory Care
Wellinks has continued to build partnerships with health plans and healthcare providers to make virtual respiratory care more widely available. Its programs focus on addressing gaps in traditional cardiopulmonary care by giving patients access to clinical guidance and monitoring from their homes.
The company says many eligible patients still have limited access to pulmonary rehabilitation, making virtual care an important option for improving treatment availability.
Looking Ahead
The new $10 million Series B funding will allow Wellinks to continue investing in its virtual care platform while expanding support for patients living with chronic respiratory diseases. As demand for remote healthcare solutions grows, the company aims to strengthen its technology and clinical services to deliver more connected, personalized respiratory care.
With this latest funding, Wellinks is positioned to continue advancing its mission of transforming cardiopulmonary care through virtual care programs, remote monitoring, and ongoing clinical support for patients and healthcare organizations.
